Literature DB >> 22309979

Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

E K Jones1, T C Kirkham.   

Abstract

BACKGROUND AND PURPOSE Endocannabinoid systems are strongly implicated in the physiological control of appetite and eating behaviour, with cannabinoid CB(1) receptor agonists and antagonists, respectively, increasing or decreasing food intake. This study examined the acute actions of the putative endocannabinoid noladin ether on food intake and eating motivation, assessing how it affects the amount of work expended by animals to obtain food. EXPERIMENTAL APPROACH Non-deprived male rats were injected systemically with noladin ether to assess its acute effects on ad libitum feeding of a standard laboratory diet. Additionally, the effects of noladin on lever pressing for palatable food were determined using a progressive ratio (PR) operant paradigm. KEY RESULTS Noladin dose dependently increased 2 h food intake, with a significant effect over 1 h after a dose of 0.5 mg·kg(-1). In the PR test, this hyperphagic dose of noladin ether promoted sustained high rates of responding and significantly increased the total number of lever presses and break-point. These latter effects were prevented by pretreatment with 1.0 mg·kg(-1) of the selective CB(1) antagonist surinabant (SR147778), that alone had no effect on responding. CONCLUSIONS AND IMPLICATIONS This is the first report of hyperphagia induced by acute noladin administration, and the first description of behavioural actions in rats. Consistent with prevailing notions about the role of endocannabinoids in appetite, a hyperphagic dose of noladin markedly increased efforts expended by animals to obtain food. Thus, noladin exerts a specific action on eating motivation; possibly promoting eating by increasing the incentive value of food.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309979      PMCID: PMC3402806          DOI: 10.1111/j.1476-5381.2012.01888.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Authors:  J Simiand; M Keane; P E Keane; P Soubrié
Journal:  Behav Pharmacol       Date:  1998-03       Impact factor: 2.293

2.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

3.  Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

4.  Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues.

Authors:  Filomena Fezza; Tiziana Bisogno; Alberto Minassi; Giovanni Appendino; Raphael Mechoulam; Vincenzo Di Marzo
Journal:  FEBS Lett       Date:  2002-02-27       Impact factor: 4.124

5.  Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol.

Authors:  Aaron N A Verty; Iain S McGregor; Paul E Mallet
Journal:  Neuropharmacology       Date:  2005-08-11       Impact factor: 5.250

6.  Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward.

Authors:  Stephen V Mahler; Kyle S Smith; Kent C Berridge
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

7.  Reduced sensitivity to reward in CB1 knockout mice.

Authors:  Carles Sanchis-Segura; Brandon H Cline; Giovanni Marsicano; Beat Lutz; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats.

Authors:  Alexa A Wakley; Erin B Rasmussen
Journal:  Pharmacol Biochem Behav       Date:  2009-07-12       Impact factor: 3.533

9.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.

Authors:  Tim C Kirkham; Claire M Williams; Filomena Fezza; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.

Authors:  Estera Páldyová; Erika Bereczki; Miklós Sántha; Tibor Wenger; Anna Borsodi; Sándor Benyhe
Journal:  Neurochem Int       Date:  2007-07-04       Impact factor: 3.921

View more
  5 in total

Review 1.  The thrifty lipids: endocannabinoids and the neural control of energy conservation.

Authors:  Nicholas V DiPatrizio; Daniele Piomelli
Journal:  Trends Neurosci       Date:  2012-05-22       Impact factor: 13.837

2.  Interactions of 2-O-arachidonylglycerol ether and ibuprofen with the allosteric and catalytic subunits of human COX-2.

Authors:  Liang Dong; Hechang Zou; Chong Yuan; Yu H Hong; Charis L Uhlson; Robert C Murphy; William L Smith
Journal:  J Lipid Res       Date:  2016-04-08       Impact factor: 5.922

3.  Quantitative analysis of performance on a progressive-ratio schedule: effects of reinforcer type, food deprivation and acute treatment with Δ⁹-tetrahydrocannabinol (THC).

Authors:  C M Olarte-Sánchez; L Valencia-Torres; H J Cassaday; C M Bradshaw; E Szabadi
Journal:  Behav Processes       Date:  2015-01-28       Impact factor: 1.777

Review 4.  To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making.

Authors:  Giovanni Hernandez; Joseph F Cheer
Journal:  Front Behav Neurosci       Date:  2015-12-17       Impact factor: 3.558

Review 5.  Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Isabella Wimmer; Johannes Berger
Journal:  Neurobiol Dis       Date:  2020-08-28       Impact factor: 5.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.